Alps Advisors Inc Amicus Therapeutics, Inc. Transaction History

Alps Advisors Inc

$14.8 Billion
Q3 2024

A detailed history of Alps Advisors Inc transactions in Amicus Therapeutics, Inc. stock. As of the latest transaction made, Alps Advisors Inc holds 227,053 shares of FOLD stock, worth $2.2 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares

227,053

Previous 231,037 1.72%

Holding current value

$2.2 Million

Previous $2.29 Million 5.81%

% of portfolio

0.02%

Previous 0.02%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	SELL	$9.55 - $12.09 $38,047 - $48,166	-3,984 Reduced 1.72%	227,053 $2.42 Million
Q2 2024 Aug 13, 2024	BUY	$9.04 - $11.75 $2.09 Million - $2.71 Million	231,037 New	231,037 $2.29 Million
Q3 2023 Nov 14, 2023	BUY	$11.78 - $13.86 $31,994 - $37,643	2,716 Added 1.3%	211,895 $2.58 Million
Q2 2023 Aug 14, 2023	BUY	$10.72 - $13.3 $2.24 Million - $2.78 Million	209,179 New	209,179 $2.63 Million
Q3 2022 Nov 14, 2022	SELL	$9.82 - $12.75 $128,916 - $167,382	-13,128 Reduced 7.9%	153,069 $1.6 Million
Q2 2022 Aug 11, 2022	SELL	$6.23 - $11.12 $757,561 - $1.35 Million	-121,599 Reduced 42.25%	166,197 $1.79 Million
Q1 2022 May 16, 2022	SELL	$7.89 - $12.48 $273,562 - $432,706	-34,672 Reduced 10.75%	287,796 $2.73 Million
Q4 2021 Feb 09, 2022	SELL	$9.82 - $12.44 $41,656 - $52,770	-4,242 Reduced 1.3%	322,468 $3.73 Million
Q3 2021 Nov 15, 2021	SELL	$8.74 - $11.84 $189,928 - $257,295	-21,731 Reduced 6.24%	326,710 $3.12 Million
Q2 2021 Aug 11, 2021	BUY	$8.71 - $10.72 $3.03 Million - $3.74 Million	348,441 New	348,441 $3.36 Million

Others Institutions Holding FOLD

# of Institutions

311

Shares Held

314M

Call Options Held

516K

Put Options Held

833K

View Full List

About AMICUS THERAPEUTICS, INC.

Ticker FOLD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 280,497,984
Market Cap $2.72B
Description
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant bas...

More about FOLD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Alps Advisors Inc, based on Form 13F filings with the SEC.

News

Stay updated on Alps Advisors Inc with notifications on news.

Account

Alps Advisors Inc Amicus Therapeutics, Inc. Transaction History